progress to endometrial carcinoma (EC). Squamous metaplasia (SM) is a common morphologic feature of EIN associated with β -catenin protein alterations. Patients with high-risk endometrial cancer (copy-number high) have frequent TP53 gene mutations and worse outcomes. This study evaluates the prognostic significance of SM, β -catenin, and p53 expression in EIN. **Methods** This retrospective study included patients with biopsy-proven EIN, subsequent hysterectomy, and evaluable tissue. Hematoxylin and Eosin (H&E) slides were reviewed to characterize SM; β -catenin and p53 expression were evaluated by immunohistochemistry (IHC).

Results 88 cases met inclusion criteria. On biopsy specimen, 11.4% (10/88) of patients had associated SM, and 2.3% (2/88) had abnormal p53 staining. 80% (8/10) of patients with SM had positive staining for β -catenin versus 2.6% (2/78) of patients lacking SM ($p < 0.001$) (figure 1). 34.1% (30/88) of patients were diagnosed with EC on subsequent hysterectomy. SM, β -catenin, and p53 expression on biopsy specimen were not correlated with a finding of neoplasia on subsequent hysterectomy (EC or EIN) ($p = 0.427$, $p = 0.104$, and $p = 0.583$, respectively).

Abstract 146 Figure 1 Biopsies from patients with EIN were evaluated via H&E. IHC was used to evaluate beta-catenin nuclear staining and p53 overexpression or null expression. Abbreviations: BCAT +, beta-catenin positive expression; WT, wild-type)

Conclusions Our findings confirm the association between SM and β -catenin abnormalities. Although rare, abnormal p53 IHC in EIN is concerning and may represent a precursor to copy-number high EC. Although these findings demonstrate molecular abnormalities within EIN, β -catenin and p53 expression do not reliably predict cancer diagnosis on final hysterectomy specimen.

IGCS20_1125

147

THE DEVELOPMENT OF THREE-DIMENSIONAL PLATFORM FOR PATIENT-DERIVED OVARIAN CANCER TISSUE REMODELLING. A SYSTEMATIC LITERATURE REVIEW

¹L Sevinyan*, ²E Velliou, ²P Gupta, ¹K Madhuri. ¹Royal Surrey County Hospital, UK; ²University of Surrey, UK

10.1136/ijgc-2020-IGCS.127

Introduction There is an unmet requirement for ex vivo tumour models that would predict drug responses and in turn help determine treatment regimens and possibly predict resistance before clinical studies. Research has shown that three-dimensional models of ovarian cancer are more realistic than two-dimensional in vitro systems as they can capture patient in vivo conditions more accurately. Most of studies aiming to recapitulate the ovarian tumour characteristics and study chemotherapy responses use ovarian cancer cell lines. However, despite the advantages of utilising cancer cell lines, they are not as informative as systems applying patient derived cells. In this review we discussed the most recent advances in the

Abstract 147 Figure 1

Abstract 147 Figure 2

creation of 3D ovarian cancer model that have used patient derived material, the challenges to overcome and future applications.

Methods Thorough systematic literature search was performed using electronic databases of MEDLINE, EMBASE and COCHRANE by 2 reviewers to identify relevant studies. The studies included in the current review met certain strict criteria.

Results 18 full papers and 11 conference abstracts were included in the review. We found that the vast majority of the 3D in vitro models developed for ovarian cancer studies are spheroid and hydrogel type models, both of which have their advantages, however do have significant limitations.

Conclusion This systematic review will provide a narrative synthesis of the platforms and methods used for three-dimensional models creation utilising patient-derived ovarian cancer material and their scientific and clinical application. We are currently exploring scaffold models to grow ovarian cancer cells ex vivo in order to personalise treatment.

IGCS20_1126

148 UNUSUAL LOCALIZATIONS OF METASTASIS FROM LOBULAR BREAST CARCINOMA: A CASE REPORT

Y Fertani*, M Bouhani, M Slimane, I Houissa, R Chargui, K Rahal. *Surgical oncology department of salah azaiez institute, Tunisia*

10.1136/ijgc-2020-IGCS.128

Introduction Pancreatic metastasis from other malignant tumor is a rare event and represent less than 5% of all pancreatic malignancies. Most common metastases arise from epithelial carcinoma such as melanoma, renal, pulmonary then lobular breast carcinoma. We report a unique case of pancreatic metastasis of myxoid breast carcinoma that occurred in a patient treated for lobular breast carcinoma 27 years ago.

Case Report We report a case of 70-year-old women with a history of lobular carcinoma of the left breast with positive hormone receptors treated in 1997. She developed distant cutaneous metastasis in the thigh and lomboarctic lymph node after 21 years of total remission. She received chemotherapy and hormonotherapy.

She presented to our department in June 2020 for obstructive jaundice evolving for 3 months. The delay was explained by the pandemic situation of COVID 19.

The clinical exam founded a severely icteric patient with hitching lesions. The breast exam was normal with the stability of the thigh cutaneous lesion. Ca15-3 was 30 UI/L and CA19.9 was 57 UI/L. MRI with cholangiography demonstrated common bile duct dilatation upstreaming of suspect mass in the head of the pancreas.

A needle biopsy of the pancreatic lesion revealed a metastatic ER/RP +, negative HER2Neu myxoid breast carcinoma.

She underwent endoscopic biliary stent and a multidisciplinary decision was to pursue chemotherapy and hormonotherapy.

Conclusion Pancreatic metastasis is a rare event that should be considered in patients with a history of breast carcinoma and obstructive jaundice. Treatment is controversial with some authors suggesting duodenopancreatectomy in patients with controlled distant disease

IGCS20_1128

149 PELVIC LYMPHADENECTOMY IN VULVAR SQUAMOUS-CELL CANCER- A MONOCENTRIC STUDY OF THE RELATION BETWEEN LYMPH-NODE INVOLVEMENT OF GROIN AND PELVIS AT THE UNIVERSITY MEDICAL CENTER HAMBURG

¹A Jaeger*, ¹I Fischer, ¹K Prieske, ¹S Mathey, ²E Vettorazzi, ¹S Kuerti, ¹C Hillen, ¹J Dieckmann, ¹B Schmalfeldt, ¹L Woelber. ¹Department of Gynecology, University Medical Center Hamburg – Eppendorf, Germany; ²Department of Medical Biometry and Epidemiology, University Medical Center Hamburg – Eppendorf, Germany

10.1136/ijgc-2020-IGCS.129

Background The value of pelvic lymphadenectomy (LAE) has been a subject of discussion since the early 1980s. This is mainly due to the fact that the relation between lymph-node involvement of the groin and pelvis is poorly understood and therewith the need for pelvic treatment in general.

Patients and Methods N=531 patients with primary vulvar squamous-cell cancer (VSCC) FIGO stage $\geq$ 1B were treated at the University Medical Center Hamburg – Eppendorf (UKE) between 1996–2018. In this analysis only patients with pelvic LAE (n=21) were analyzed with regard to prognosis and the relation of groin and pelvic lymph-node involvement.

Results The majority had T1b/T2 tumors (n=15, 71.4%) with a median diameter of 40 mm (11–110 mm). Only 17/21 patients were inguinally node-positive. Pelvic nodal involvement without groin metastases was not observed. 6/17 node-positive patients also had pelvic nodal metastases (35.3%; median number of affected pelvic nodes 2.5(1–8)). These 6 patients were highly node positive with median 4.5 (2–9) affected groin nodes. With regard to the metastatic spread between groins and pelvis, no contralateral spread was observed.

Four recurrences were observed after a median FU of 33.5 months. No pelvic recurrences were observed in the pelvic nodal positive group; while 33.3% experienced recurrences at distant sites (2/6). Patients with pelvic metastasis at first diagnosis had a progression-free survival of only 25.6 months.

Conclusion A relevant risk for pelvic nodal involvement only seems to be present in highly node-positive disease, therefore pelvic nodal staging (and radiotherapy) is probably unnecessary in the majority of patients with node-positive VSCC.

IGCS20_1130

150 THE SURVIVAL OUTCOME AND PROGNOSTIC FACTORS OF EARLY STAGE OVARIAN CANCER, FIGO STAGE IA AND IC, AFTER FERTILITY-SPARING SURGERY (FSS): A RETROSPECTIVE COHORT STUDY

M Agulto-Mercadal*, LM Cole, RA Santos. *Jose R. Reyes memorial medical center, philippines*

10.1136/ijgc-2020-IGCS.130

Objectives Management of early stage ovarian cancer among women of reproductive age remains to be a challenge. This study aimed to determine the survival outcome and predictors of recurrence and survival among these women, with stage IA and IC ovarian cancer after unilateral salpingo-oophorectomy.